Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1985 1
1987 1
1988 2
1989 3
1990 3
1991 12
1992 6
1993 3
1994 16
1995 6
1996 11
1997 22
1998 13
1999 24
2000 13
2001 14
2002 20
2003 16
2004 19
2005 15
2006 14
2007 21
2008 11
2009 15
2010 20
2011 15
2012 19
2013 22
2014 31
2015 63
2016 77
2017 58
2018 70
2019 90
2020 93
2021 103
2022 58
Text availability
Article attribute
Article type
Publication date

Search Results

901 results
Results by year
Filters applied: . Clear all
Page 1
Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.
Younossi Z, Tacke F, Arrese M, Chander Sharma B, Mostafa I, Bugianesi E, Wai-Sun Wong V, Yilmaz Y, George J, Fan J, Vos MB. Younossi Z, et al. Hepatology. 2019 Jun;69(6):2672-2682. doi: 10.1002/hep.30251. Hepatology. 2019. PMID: 30179269 Free article. Review.
Because of the close association of NAFLD with type 2 diabetes (T2DM) and obesity, the latest models predict that the prevalence of NAFLD and NASH will increase, causing a tremendous clinical and economic burden and poor patient-reported outcomes. Nonetheless, there is no …
Because of the close association of NAFLD with type 2 diabetes (T2DM) and obesity, the latest models predict that the prevalence of NAFLD an …
The Use of Rifaximin in Patients With Cirrhosis.
Caraceni P, Vargas V, Solà E, Alessandria C, de Wit K, Trebicka J, Angeli P, Mookerjee RP, Durand F, Pose E, Krag A, Bajaj JS, Beuers U, Ginès P; Liverhope Consortium. Caraceni P, et al. Hepatology. 2021 Sep;74(3):1660-1673. doi: 10.1002/hep.31708. Epub 2021 Jun 7. Hepatology. 2021. PMID: 33421158 Free PMC article. Review.
However, the use of rifaximin for prevention or treatment of other complications, including spontaneous bacterial peritonitis or other bacterial infections, is not accepted because evidence by clinical trials is still very weak. The present review deals in the first part w …
However, the use of rifaximin for prevention or treatment of other complications, including spontaneous bacterial peritonitis or other bacte …
Abnormal Liver Function Tests in Patients With COVID-19: Relevance and Potential Pathogenesis.
Bertolini A, van de Peppel IP, Bodewes FAJA, Moshage H, Fantin A, Farinati F, Fiorotto R, Jonker JW, Strazzabosco M, Verkade HJ, Peserico G. Bertolini A, et al. Hepatology. 2020 Nov;72(5):1864-1872. doi: 10.1002/hep.31480. Epub 2020 Oct 20. Hepatology. 2020. PMID: 32702162 Free PMC article. Review.
In conclusion, these initial observations suggest that the prevalence of abnormal LFTs is high in COVID-19 patients, but that the clinical relevance is limited and that treatment is not required. The mechanisms underlying abnormal LFTs in COVID-19 are likely multifactorial …
In conclusion, these initial observations suggest that the prevalence of abnormal LFTs is high in COVID-19 patients, but that the clinica
The Prevalence of Wilson's Disease: An Update.
Sandahl TD, Laursen TL, Munk DE, Vilstrup H, Weiss KH, Ott P. Sandahl TD, et al. Hepatology. 2020 Feb;71(2):722-732. doi: 10.1002/hep.30911. Epub 2020 Jan 31. Hepatology. 2020. PMID: 31449670 Review.
The "Scheinberg-Sternlieb Estimate" is still widely used, although more recent clinical and genetic studies of higher quality are now available. In the present study, we included these data to update the prevalence estimate. ...We identified 4 recent clinical studie …
The "Scheinberg-Sternlieb Estimate" is still widely used, although more recent clinical and genetic studies of higher quality are now …
NAFLD: Reporting Histologic Findings in Clinical Practice.
Brunt EM, Kleiner DE, Carpenter DH, Rinella M, Harrison SA, Loomba R, Younossi Z, Neuschwander-Tetri BA, Sanyal AJ; American Association for the Study of Liver Diseases NASH Task Force. Brunt EM, et al. Hepatology. 2021 May;73(5):2028-2038. doi: 10.1002/hep.31599. Hepatology. 2021. PMID: 33111374 Review.
The role of liver biopsy in NASH has evolved along with the increased recognition of the significance of this disease, and the unmet medical need it presents. Drug development and clinical trials are rapidly growing, as are noninvasive tests for markers of steatosis, infla …
The role of liver biopsy in NASH has evolved along with the increased recognition of the significance of this disease, and the unmet medical …
Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference.
Llovet JM, Villanueva A, Marrero JA, Schwartz M, Meyer T, Galle PR, Lencioni R, Greten TF, Kudo M, Mandrekar SJ, Zhu AX, Finn RS, Roberts LR; AASLD Panel of Experts on Trial Design in HCC. Llovet JM, et al. Hepatology. 2021 Jan;73 Suppl 1:158-191. doi: 10.1002/hep.31327. Epub 2020 Sep 9. Hepatology. 2021. PMID: 32430997 Review. No abstract available.
Application of Artificial Intelligence for the Diagnosis and Treatment of Liver Diseases.
Ahn JC, Connell A, Simonetto DA, Hughes C, Shah VH. Ahn JC, et al. Hepatology. 2021 Jun;73(6):2546-2563. doi: 10.1002/hep.31603. Hepatology. 2021. PMID: 33098140 Review.
This review article will provide a comprehensive overview of hepatology-focused AI research, discuss some of the barriers to clinical implementation and adoption, and suggest future directions for the field....
This review article will provide a comprehensive overview of hepatology-focused AI research, discuss some of the barriers to clinical
Outcome of COVID-19 in Patients With Autoimmune Hepatitis: An International Multicenter Study.
Efe C, Dhanasekaran R, Lammert C, Ebik B, Higuera-de la Tijera F, Aloman C, Rıza Calışkan A, Peralta M, Gerussi A, Massoumi H, Catana AM, Torgutalp M, Purnak T, Rigamonti C, Gomez Aldana AJ, Khakoo N, Kacmaz H, Nazal L, Frager S, Demir N, Irak K, Ellik ZM, Balaban Y, Atay K, Eren F, Cristoferi L, Batıbay E, Urzua Á, Snijders R, Kıyıcı M, Akyıldız M, Ekin N, Carr RM, Harputluoğlu M, Hatemi I, Mendizabal M, Silva M, Idilman R, Silveira M, Drenth JPH, Assis DN, Björnsson E, Boyer JL, Invernizzi P, Levy C, Schiano TD, Ridruejo E, Wahlin S. Efe C, et al. Hepatology. 2021 Jun;73(6):2099-2109. doi: 10.1002/hep.31797. Hepatology. 2021. PMID: 33713486 Free PMC article.
The outcomes of patients with AIH were compared to a propensity score-matched cohort of patients without AIH but with chronic liver diseases (CLD) and COVID-19. The frequency and clinical significance of new-onset liver injury (alanine aminotransferase > 2 the upper lim …
The outcomes of patients with AIH were compared to a propensity score-matched cohort of patients without AIH but with chronic liver diseases …
Lysyl Oxidase (LOX) Family Members: Rationale and Their Potential as Therapeutic Targets for Liver Fibrosis.
Chen W, Yang A, Jia J, Popov YV, Schuppan D, You H. Chen W, et al. Hepatology. 2020 Aug;72(2):729-741. doi: 10.1002/hep.31236. Hepatology. 2020. PMID: 32176358 Review.
Inhibition of the LOX family as a whole and of LOX, LOXL1, and LOXL2 specifically has been shown to suppress fibrosis progression and accelerate its reversal in rodent models of cardiac, renal, pulmonary, and liver fibrosis. Recent disappointing clinical trials with a mono …
Inhibition of the LOX family as a whole and of LOX, LOXL1, and LOXL2 specifically has been shown to suppress fibrosis progression and accele …
901 results